PURPOSE: A pharmaceutical composition containing pilocarpine or pharmaceutically acceptable salt thereof is provided to relieve pain, xerostomia, keratoconjunctivitis sicca, and irritable bowel syndrome symptom. CONSTITUTION: A pharmaceutical composition for treating fibromyalgia syndrome contains pilocarpine or pharmaceutically acceptable salt thereof. The salt is pilocarpine hydrochloride. The composition also contains gabapentine, pregabalin, extract from vaccinia virus-vaccinated rat inflamm...

FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely psychiatry. A method of treating panic disorder involves prescribing psychopharmacotherapy

The present invention includes benzodiazepine compositions formulated for intranasal administration comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble the first solvent capable of penetrating nasal mucosal tissue and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including but not limited to panic attacks muscle spasms anxiety and seizures. In one...

Disclosed is a non-aqueous composition for intranasal delivery of a benzodiazepine drug which comprises (i) a benzodiazepine drug such as diazepam, lorazepam, clonazepam or midazolam

Disclosed herein is a pharmaceutical compositions for transmucosal administration to a mammal, comprising a solvent system consisting essentially of an alkyl ether solvent in which clonazepam is soluble, wherein the alkyl ether solvent is selected from the group consisting of 1,2-dimethoxyethane, diethyleneglycol monomethylether, diethyleneglycol monoethylether and diethyleneglycol diethylether, the solvent capable of penetrating nasal mucosal tissue, and a therapeutically effective amount of cl...

Disclosed herein is a pharmaceutical composition for transmucosal administration to a mammal comprising a solvent system consisting essentially of a first solvent in which clonazepam is soluble, wherein the first solvent is composed of one or more components selected from the group consisting of diethyleneglycol monoethylether and tetrahydrofurfuryl alcohol polyethyleneglycol ether, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which clonazepam is less so...